We enter 2018 with fully a funded Phase III program and a strong cash position to support our emerging pipeline of drug candidates. Read Our 2017 Annual Review.

Our clinical development pipeline features three drug candidates, each with distinct, well defined mechanisms of action for attacking cancer.
Read Our 2017 Annual Review

In August we announced our First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia.
 Read Our 2017 Annual Review

LATEST NEWS

Presentation at BioCentury NewsMakers in the Biotech Industry
Webcast | Slides


Fireside Chat with CEO at Wells Fargo Healthcare Conference
Webcast


MEI Pharma Announces Exclusive License Agreement with Presage Biosciences for Voruciclib
Press Release


MEI Pharma Reports Fiscal Year 2017 Results
Press Release | Webcast


First Patient Dosed in Pivotal Phase 3 Study of Pracinostat and Azacitidine in AML
Press Release


First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in MDS
Press Release